The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...
Researchers sought to compare the safety and efficacy of pirtobrutinib monotherapy vs bendamustine plus rituximab among treatment-naïve patients with CLL/SLL.
Bruton tyrosine kinase inhibitors (BTKis) are a cornerstone of chronic lymphocytic leukemia (CLL) therapy, with newer second-generation agents developed to maintain efficacy while improving ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company, a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, ...
Margaret Krackeler, MD, of Kaiser Permanente Northern California, discusses the growing role of real-world treatment data in CLL and other cancers.
Retrospective ONCare Alliance Network data showed lower odds of new or worsened hypertension with acalabrutinib versus ibrutinib (OR 0.27; 95% CI, 0.074–0.98). Despite older age and higher baseline ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...
Please see the Important Safety Information section below, including Boxed WARNINGS for Breyanzi regarding Cytokine Release ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged ...
In this article, we will look at the 12 Best Healthcare Stocks Under $50 to Invest In. On January 27, Jared Holz, healthcare ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...
Eli Lilly and Company (NYSE:LLY) Q4 2025 Earnings Call Transcript February 4, 2026 Eli Lilly and Company beats earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results